Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03052608
Title	A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Pfizer
Indications	lung non-small cell carcinoma
Therapies	Lorlatinib Crizotinib
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| POL \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BEL \| AUS \| ARG